alpha-Interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia

被引:30
作者
Giardini, C
Galimberti, M
Lucarelli, G
Polchi, P
Angelucci, E
Baronciani, D
Erer, B
Gaziev, D
Piga, A
DiGregorio, F
Romeo, MA
Mangiagli, A
Petrelli, E
Muretto, P
机构
[1] AZIENDA OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY
[2] UNIV TURIN,IST CLIN PEDIAT,CTR MICROCITEMIE,TURIN,ITALY
[3] UNIV CATANIA,DIV PEDIAT,CATANIA,ITALY
[4] OSPED UMBERTO 1,DIV PEDIAT,SIRACUSA,ITALY
[5] AZIENDA OSPED PESARO,DIV MALATTIE INFETTIVE,I-61100 PESARO,ITALY
[6] AZIENDA OSPED PESARO,SERV ANAT PATOL,I-61100 PESARO,ITALY
关键词
interferon; HCV; thalassemia; BMT;
D O I
10.1038/sj.bmt.1700968
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
No experience has been reported to date in treating chronic hepatitis C virus (HCV) infection with interferon (IFN) therapy after BMT, mainly due to concerns related to the impact of an immunomodulatory drug in patients who are immunologic and haematologic chimeras, However, chronic inflammatory activity related to HCV infection results in a chronic fibrogenous mechanism potentially leading to liver cirrhosis and hepatocellular carcinoma. Moreover, patients transplanted for P-thalassemia could be at greater risk because of concomitant iron overload and pre-existing fibrous liver damage, Eleven patients with serological, biochemical, histological and molecular biological evidence of HCV infection were included in the study and treated for 6-12 months with recombinant IFN 24-65 months following BMT, The serum alanine aminotransferase (ALT) was persistently elevated (range 85-1242 U/l; mean 416) for at least 1 year prior to IFN treatment, Ten patients completed the protocol; five were considered as responders to treatment, In these five patients the liver histology showed an overall reduction of inflammation and necrosis: histological inflammatory activity improved from chronic active hepatitis (CAH) to chronic persistent hepatitis (three patients) or minimal residual inflammatory activity (two patients), The Knodell total activity score varied from 5.4 (range 3-9) to 1.4 (range 1-2; P = 0.05), All responding patients revealed negativization of serum HCV-RNA, that has been persistent in four (follow-up 1-3 years), ALT level fell to 15-80 U/l (mean 52; P = 0.0027), No major complications occurred during the therapy and no influence on marrow engraftment parameters were noted. We conclude that IFN therapy does not adversely interfere with engraftment and that it is a feasible therapy for treatment of chronic hepatitis C virus after BMT.
引用
收藏
页码:767 / 772
页数:6
相关论文
共 33 条
  • [21] BONE-MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA
    LUCARELLI, G
    GALIMBERTI, M
    POLCHI, P
    ANGELUCCI, E
    BARONCIANI, D
    GIARDINI, C
    POLITI, P
    DURAZZI, SMT
    MURETTO, P
    ALBERTINI, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (07) : 417 - 421
  • [22] FATE OF IRON STORES IN THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION
    LUCARELLI, G
    ANGELUCCI, E
    GIARDINI, C
    BARONCIANI, D
    GALIMBERTI, M
    POLCHI, P
    BARTOLUCCI, M
    MURETTO, P
    ALBERTINI, F
    [J]. LANCET, 1993, 342 (8884) : 1388 - 1391
  • [23] MARUTA A, 1994, BONE MARROW TRANSPL, V13, P417
  • [24] MURETTO P, 1994, LIVER, V14, P14
  • [25] SURVIVAL AND CAUSES OF DEATH IN CIRRHOTIC AND IN NONCIRRHOTIC PATIENTS WITH PRIMARY HEMOCHROMATOSIS
    NIEDERAU, C
    FISCHER, R
    SONNENBERG, A
    STREMMEL, W
    TRAMPISCH, HJ
    STROHMEYER, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (20) : 1256 - 1262
  • [26] HEPATIC IRON CONCENTRATION AS A PREDICTOR OF RESPONSE TO INTERFERON-ALFA THERAPY IN CHRONIC HEPATITIS-C
    OLYNYK, JK
    REDDY, KR
    DIBISCEGLIE, AM
    JEFFERS, LJ
    PARKER, TI
    RADICK, JL
    SCHIFF, ER
    BACON, BR
    [J]. GASTROENTEROLOGY, 1995, 108 (04) : 1104 - 1109
  • [27] POJNARD T, 1995, NEW ENGL J MED, V332, P1457
  • [28] RHODES J, 1993, CLIN EXP IMMUNOL, V53, P739
  • [29] RISDON RA, 1975, J PATHOL, V116, P83, DOI 10.1002/path.1711160204
  • [30] Samson D, 1996, BONE MARROW TRANSPL, V17, P759